Dr Erik Goluboff: A Leader in Urologic Cancer Research”


Dr Erik Goluboff is a highly respected medical professional in the field of urology, with a career spanning nearly three decades. He currently serves as the Principal Medical Lead of Genentech’s drug development program in urologic cancers. He is responsible for leading the development and execution of clinical trials for new treatments in this area.
Dr Erik Goluboff received his medical degree from the New York University School of Medicine and completed his residency in urology at New York-Presbyterian Hospital/Weill Cornell Medical Center. He is board certified in urology and is a fellow of the American College of Surgeons.
Throughout his career, Dr Erik Goluboff has held several high-ranking positions at notable organizations, including serving as the Director of Urologic Oncology at North Shore-Long Island Jewish Health System and as an Associate Professor of Urology at the Hofstra Northwell School of Medicine. He received his medical degree from Johns Hopkins University in 1990 and is the Medical Lead of the urologic cancer drug development program at Genentech.
Dr Erik Goluboff has extensive experience treating urologic cancers, focusing on prostate cancer. He has been involved in developing and implementing several new prostate cancer treatments, including androgen deprivation therapy, radiation therapy, and surgery. He has also been involved in developing new drugs to treat advanced prostate cancer, including immunotherapies and targeted therapies.
Dr Erik Goluboff is an active researcher, having published numerous articles in peer-reviewed journals on urologic cancer. He also frequently lectures on urologic cancer and has presented his research at numerous national and international conferences.
In addition to his work in the field of urologic cancer, Dr Erik Goluboff is also actively involved in the broader medical community. He serves on the board of several professional organizations, including the American Urological Association and the Prostate Cancer Foundation. He is also a member of several professional societies, including the American Society of Clinical Oncology and the International Society of Urologic Oncology.